Trinity Biotech plc (NASDAQ:TRIB) — Stock Price
Trinity Biotech plc (NASDAQ:TRIB) is currently trading at $13.20 USD, up 6.19% today. Over the past 52 weeks, shares have ranged between $0.30 and $13.20. This page tracks Trinity Biotech plc's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see TRIB stock market capitalisation.
Trinity Biotech plc (TRIB) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Trinity Biotech plc's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Trinity Biotech plc Income Statement — Revenue, Profit & Earnings by Year
Trinity Biotech plc's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | $61.55 Million | $56.83 Million | $62.52 Million | $81.15 Million | $101.98 Million |
| Cost of Revenue | $40.11 Million | $37.38 Million | $52.73 Million | $54.89 Million | $53.40 Million |
| Gross Profit | $21.44 Million | $19.45 Million | $22.05 Million | $33.45 Million | $48.58 Million |
| Research & Development | $4.54 Million | $4.38 Million | $4.14 Million | $4.50 Million | $5.08 Million |
| SG&A | $28.82 Million | $31.15 Million | $29.17 Million | $24.68 Million | $25.07 Million |
| Total Operating Expenses | $42.61 Million | $46.49 Million | $32.96 Million | $29.52 Million | $48.50 Million |
| Operating Income | $-21.16 Million | $-27.05 Million | $-15.27 Million | $3.94 Million | $82.00K |
| EBITDA | $-16.91 Million | $-24.10 Million | $-16.71 Million | $10.59 Million | $3.19 Million |
| EBIT | $-18.77 Million | $-25.87 Million | $-19.05 Million | $7.85 Million | $118.00K |
| Interest Expense | $9.56 Million | $10.15 Million | $24.73 Million | $7.10 Million | $6.75 Million |
| Income Before Tax | $-30.73 Million | $-36.93 Million | $-43.78 Million | $-1.92 Million | $-6.63 Million |
| Income Tax Expense | $486.00K | $-59.00K | $-194.00K | $-74.00K | $-620.00K |
| Net Income | $-31.79 Million | $-24.02 Million | $-41.00 Million | $875.00K | $-6.39 Million |
Trinity Biotech plc Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Trinity Biotech plc's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | $103.29 Million | $59.44 Million | $92.10 Million | $118.89 Million | $130.40 Million |
| Total Current Assets | $41.12 Million | $39.04 Million | $46.67 Million | $72.69 Million | $83.30 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | $0.00 |
| Net Receivables | $14.60 Million | $13.38 Million | $15.65 Million | $15.71 Million | $24.59 Million |
| Inventory | $19.37 Million | $19.93 Million | $22.50 Million | $29.12 Million | $30.22 Million |
| Property, Plant & Equipment | — | — | — | $5.92 Million | $8.55 Million |
| Goodwill | $13.84 Million | $0.00 | $12.54 Million | $12.54 Million | $12.59 Million |
| Total Liabilities | $138.47 Million | $83.38 Million | $94.28 Million | $119.21 Million | $132.62 Million |
| Total Current Liabilities | $32.09 Million | $15.04 Million | $17.34 Million | $100.49 Million | $27.06 Million |
| Long-term Debt | $87.79 Million | $54.65 Million | $58.05 Million | — | $83.88 Million |
| Net Debt | $95.60 Million | $63.74 Million | $51.68 Million | $73.25 Million | $77.01 Million |
| Total Stockholder Equity | $-35.18 Million | $-23.95 Million | $-2.18 Million | $-319.00K | $-2.22 Million |
| Retained Earnings | $-79.12 Million | $-48.64 Million | $-26.70 Million | $12.56 Million | $10.57 Million |
Trinity Biotech plc Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Trinity Biotech plc generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-4.19 Million | $-11.56 Million | $-921.00K | $13.24 Million | $23.75 Million |
| Capital Expenditures | $10.06 Million | $803.00K | $5.98 Million | $8.69 Million | $10.20 Million |
| Free Cash Flow | $-14.26 Million | $-12.36 Million | $-6.90 Million | $4.55 Million | $13.56 Million |
| Investing Cash Flow | $-22.97 Million | $24.76 Million | $-5.98 Million | $-8.69 Million | $-10.20 Million |
| Financing Cash Flow | $28.81 Million | $-16.04 Million | $-12.32 Million | $-6.02 Million | $-2.72 Million |
| Dividends Paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Stock-Based Compensation | $1.32 Million | $2.07 Million | $1.75 Million | $1.10 Million | $792.00K |
| Depreciation | $1.86 Million | $1.78 Million | $2.33 Million | $2.74 Million | $3.08 Million |
| Change in Cash | $1.48 Million | $-2.89 Million | $-19.33 Million | $-1.42 Million | $10.93 Million |
Trinity Biotech plc Earnings History — EPS Actual vs. Analyst Estimates
Track Trinity Biotech plc's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Dec 23, 2025 | -0.40 | 0.00 | — |
| May 16, 2025 | -1.24 | -0.05 | -2380.00% |
| Dec 31, 2024 | -0.88 | -0.30 | -192.73% |
| Oct 02, 2024 | -1.10 | -0.40 | -175.00% |
| Aug 14, 2024 | -0.71 | -0.65 | -9.23% |
| Apr 04, 2024 | -3.59 | -0.12 | -2890.67% |
| Jan 31, 2024 | -0.18 | -0.14 | -25.00% |
| Oct 03, 2023 | -0.15 | -0.09 | -66.67% |